Intensive chemotherapy for XXXX : combination of @entity900 , @entity632 , etoposide and @entity6030 with granulocyte @entity1261 support. Chemotherapy Committee, The Japanese Society of Thyroid Surgery.

@entity632 @entity1 @entity1262 @entity137 @entity1261 @entity900 @entity409 @entity1442 @entity1431 @entity2867 @entity6030
The Japanese Society of Thyroid Surgery undertook a pilot study of treatment for @entity2867 in a cooperative setting. The treatment consisted of @entity900 40 mg/m2 drip intravenous infusion (div), day 1, @entity632 60 mg/m2 iv, day 1, etoposide 100 mg/m2/day div, days 1-3, @entity6030 5 mg/body/day sc, days 1-5 and @entity1261 ( @entity1261 ) 2 micrograms/kg/day sc, days 6-14. This was scheduled to be repeated every 3 weeks. Local radiation therapy was added for @entity1 in whom it was indicated. A total of 17 @entity1 (mean age, 66 yr) were enrolled. Ten @entity1 had @entity1442 with measurable lesions and 2 @entity1 experienced partial remission lasting 2 and 3 months, respectively. Six of 7 @entity1 were treated with the same modality of treatment as an adjuvant. Three died of progressive disease after 3-7 months and three others have survived for 3-11 months. The @entity137 of the chemotherapy were mainly bone marrow suppression, despite @entity1261 support. Transient @entity409 was also noticed. These results indicate that this combined a treatment can be given to @entity1 with acceptable @entity137 . The degree of @entity1431 was greater than expected, partly due to the advanced age of the @entity1 and the low dose of @entity1261 . In addition, 8 available thyroid specimens were examined for the @entity1262 gene and @entity1262 , but all were negative. Further study of @entity2867 by this cooperative group will be carried out.
